Translate

Thursday, March 1, 2018

thumbnail

ZSAN Zosano Pharma Corporation gains 21% Mar 1, 2018

Zosano Pharma Corporation, a clinical stage pharmaceutical company, develops a proprietary intracutaneous delivery system to administer drugs through the skin for rapid symptom relief to patients. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. http://www.priceseries.com/trade/ZSAN-Zosano-Pharma-Corporation-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2018022320180301.html

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive